Antibodies to tip-1 and grp78
AssigneeWashington University
InventorsDennis E. Hallahan, Heping Yan
Life of this patent
Estimating the term…
Abstract
The present invention is directed towards isolated antibodies that bind to GRP78.
Claims9
An isolated antibody that binds to 78-kDa glucose-regulated protein (GRP78), wherein the antibody comprises a heavy chain variable domain comprising a CDR1, CDR2, and a CDR3, wherein the heavy chain variable domain CDR1 comprises SEQ ID NO:
- 15, the heavy chain variable region domain CDR2 comprises SEQ ID NO:16, and the heavy chain variable region domain CDR3 comprises SEQ ID NO:17;
- and a light chain variable domain comprising a CDR1, CDR2, and CDR3, wherein the light chain variable domain CDR1 comprises SEQ ID NO:18, the light chain variable region domain CDR2 comprises SEQ ID NO:19, and the light chain variable region domain CDR3 comprises SEQ ID NO:20.
A method of enhancing radiotherapy in a subject using an antibody that binds to 78-kDa glucose-regulated protein (GRP78), wherein the antibody is conjugated directly or indirectly to a payload selected from the group consisting of a therapeutic agent, an imaging agent, or a combination thereof, the method comprising administering a pharmacologically effective amount of antibody to the subject, such that radiotherapy is enhanced.
A method of imaging cancer in a subject, using an antibody that binds to 78-kDa glucose-regulated protein (GRP78), wherein the antibody is conjugated to an imaging agent, the method comprising administering the conjugated GRP78 to the subject, and imaging cancer in a subject.
Dependencies are inferred from the claim text.